These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 28034070)

  • 1. Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.
    Yamaguchi M; Suzuki R; Oguchi M; Asano N; Amaki J; Akiba T; Maeda T; Itasaka S; Kubota N; Saito Y; Kobayashi Y; Itami J; Ueda K; Miyazaki K; Ii N; Tomita N; Sekiguchi N; Takizawa J; Saito B; Murayama T; Ando T; Wada H; Hyo R; Ejima Y; Hasegawa M; Katayama N
    J Clin Oncol; 2017 Jan; 35(1):32-39. PubMed ID: 28034070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.
    Yamaguchi M; Suzuki R; Kim SJ; Ko YH; Oguchi M; Asano N; Miyazaki K; Terui Y; Kubota N; Maeda T; Kobayashi Y; Amaki J; Soejima T; Saito B; Shimoda E; Fukuhara N; Tsukamoto N; Shimada K; Choi I; Utsumi T; Ejima Y; Kim WS; Katayama N
    Cancer Sci; 2018 Jun; 109(6):2056-2062. PubMed ID: 29601137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
    Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
    Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of NK/T-cell lymphoma: current situations and prospectives].
    Yamaguchi M
    Rinsho Ketsueki; 2018; 59(5):588-593. PubMed ID: 29877250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
    Miyazaki K; Suzuki R; Oguchi M; Taguchi S; Amaki J; Maeda T; Kubota N; Maruyama D; Terui Y; Sekiguchi N; Takizawa J; Tsukamoto H; Murayama T; Ando T; Matsuoka H; Hasegawa M; Wada H; Sakai R; Kameoka Y; Tsukamoto N; Choi I; Masaki Y; Shimada K; Fukuhara N; Utsumi T; Uoshima N; Kagami Y; Asano N; Ejima Y; Katayama N; Yamaguchi M
    Hematol Oncol; 2022 Oct; 40(4):667-677. PubMed ID: 35142384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
    Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
    Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
    Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
    Yamaguchi M; Tobinai K; Oguchi M; Ishizuka N; Kobayashi Y; Isobe Y; Ishizawa K; Maseki N; Itoh K; Usui N; Wasada I; Kinoshita T; Ohshima K; Matsuno Y; Terauchi T; Nawano S; Ishikura S; Kagami Y; Hotta T; Oshimi K
    J Clin Oncol; 2009 Nov; 27(33):5594-600. PubMed ID: 19805668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin.
    Yamaguchi M; Suzuki R; Miyazaki K; Amaki J; Takizawa J; Sekiguchi N; Kinoshita S; Tomita N; Wada H; Kobayashi Y; Niitsu N; Ando T; Maeda T; Saito B; Matsuoka H; Sakai R; Kubota N; Masaki Y; Kameoka Y; Asano N; Oguchi M; Katayama N
    Ann Hematol; 2019 Jul; 98(7):1647-1655. PubMed ID: 31001658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL).
    Lee J; Cho SG; Chung SM; Ryu MR; Kim SH; Jang HS; Choi BO
    Ann Hematol; 2013 Mar; 92(3):333-43. PubMed ID: 23180438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma.
    Makita S; Tobinai K
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):239-253. PubMed ID: 28340876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful full-dose DeVIC therapy in a patient with advanced-stage extranodal natural killer/T-cell lymphoma refractory to L-asparaginase.
    Watanabe J; Makita S; Ito Y; Hatta S; Suzuki T; Yuda S; Maeshima AM; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kim SW; Izutsu K
    Ann Hematol; 2018 Sep; 97(9):1739-1740. PubMed ID: 29663028
    [No Abstract]   [Full Text] [Related]  

  • 13. Extranodal natural killer/T cell lymphoma: we should and we can do more.
    Ying Z; Zhu J
    Chin Clin Oncol; 2015 Mar; 4(1):12. PubMed ID: 25841719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK/T Cell Lymphoma: Updates in Therapy.
    Suzuki R
    Curr Hematol Malig Rep; 2018 Feb; 13(1):7-12. PubMed ID: 29368155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and future management of NK/T-cell lymphoma based on clinical trials.
    Yamaguchi M
    Int J Hematol; 2012 Nov; 96(5):562-71. PubMed ID: 23073619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
    Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
    Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.
    Wang X; Zhang L; Liu X; Li X; Li L; Fu X; Sun Z; Wu J; Zhang X; Yan J; Chang Y; Nan F; Zhou Z; Wu X; Tian L; Ma M; Li Z; Yu H; Zhu L; Wang Y; Shi C; Feng X; Li J; Ding M; Zhang J; Dong M; Xue H; Wang J; Zou L; Su L; Wu J; Liu L; Bao H; Zhang L; Guo Y; Guo S; Lu Y; Young KH; Li W; Zhang M
    JAMA Oncol; 2022 Jul; 8(7):1035-1041. PubMed ID: 35708709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIE extranodal natural killer/T-cell lymphoma, nasal type.
    Tian S; Li R; Wang T; Wang S; Tao R; Hu X; Ding H
    Cancer Med; 2019 Jul; 8(7):3349-3358. PubMed ID: 31050212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy.
    Motomura K; Natsume A; Fujii M; Ito M; Momota H; Wakabayashi T
    Leuk Lymphoma; 2011 Nov; 52(11):2069-75. PubMed ID: 21745167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.
    Dong LH; Zhang LJ; Wang WJ; Lei W; Sun X; Du JW; Gao X; Li GP; Li YF
    Leuk Lymphoma; 2016 Jul; 57(7):1600-6. PubMed ID: 26726970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.